LNSRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31

LENSAR, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$5.75−0.05 (-0.86%)

Close on Oct 19, 2026

Market cap: $132.41M
P/E (TTM): –
Dividend yield: –

LENSAR, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31
Revenue	58	53	42	35	34	26	31
Cost of Revenue	31	28	21	15	17	12	17
Gross Profit	27	26	21	20	18	14	13
Research & Development	5.62	5.33	6.14	12	12	7.55	7.57
Selling, General & Admin	45	26	26	27	24	24	17
Advertising Expenses	0.73	0.58	0.62	0.47	–	–	–
Operating Income	-25	-11	-12	-20	-20	-19	-13
Interest Expense	–	–	–	–	–	1.34	2.00
Other Non-Operating Income	0.64	0.66	0.70	0.26	0.05	0.07	0.06
Gain (Loss) on Sale of Assets	-0.06	–	-0.01	-0.01	-0.13	-0.03	–
Pretax Income	-34	-31	-14	-20	-20	-20	-15
Net Income incl. Noncontrolling Interests	-34	-31	-14	-20	-20	-20	-15
Net Income	-34	-31	-14	-20	-20	-20	-15
Net Income to Common	-34	-31	-14	-20	-20	-20	-15
EPS (Basic)(per share)	-2.87	-2.73	-1.31	-1.96	-2.09	-4.28	-13.70
EPS (Diluted)(per share)	-2.87	-2.73	-1.31	-1.96	-2.09	-4.28	-13.70
Shares Outstanding (Basic, Weighted)(shares)	12	12	11	10	9.37	4.62	1.07
Shares Outstanding (Diluted, Weighted)(shares)	12	12	11	10	9.37	4.62	1.07
Provision for Credit Losses	-0.01	0.00	0.02	0.01	0.05	0.00	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 48.3%
Operating margin: -13.5%
Net margin: 57.6%
Return on equity, FY2025: 324.1%

Financial strength

Current ratio: 2.39
Debt to equity: 0.25
Debt to assets: 5.4%
Cash to current liabilities: 69.1%

Valuation

P/E ratio: –
Price to sales: 2.20
Price to book: 8.88
Dividend yield: –